Objective of the merger
Boston Biomedical and Tolero are both engaged in research and development of oncology. Consolidation of the two companies is aimed at further increasing corporate value through improvement of business efficiency, efficient use of management resources, increase in our market presence, and further strengthening of cooperation with external partners
Contact:
Tel: +81-6-6203-1407
Financial impact on group performance Because the merger is between two of our consolidated subsidiaries, the impact on our consolidated results will be minimal.
(C) 2020 Electronic News Publishing, source